DANA-FARBER CANCER INSTITUTE
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $1B
- Transactions
- 14,402
- Companies
- 40
- Average per transaction
- $71,054
Who reported the payments
| Genentech, Inc. | $325,118,454 |
| AstraZeneca | $145,092,824 |
| Astrazeneca UK Limited | $57,642,145 |
| E.r. Squibb & Sons, L.L.C. | $52,108,458 |
| Merck | $50,920,959 |
| Pfizer | $48,130,231 |
| AbbVie | $36,130,251 |
| Bristol Myers Squibb | $24,367,953 |
| Pharmacyclics LLC, An Abbvie Company | $22,383,729 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18,827,591 |
| Servier Affaires Medicales | $17,303,861 |
| Daiichi Sankyo Inc. | $15,768,414 |
| Servier Bioinnovation | $14,874,954 |
| Novartis | $14,201,129 |
| Servier Pharmaceuticals LLC | $14,028,930 |
| Fujirebio Diagnostics, Incorporated | $13,838,496 |
| Amgen | $12,362,141 |
| Gilead | $10,188,538 |
| Eli Lilly | $9,312,336 |
| Clinigen, Inc. | $7,727,000 |
| Beckman Coulter, Inc. | $6,634,757 |
| Sumitomo Pharma Co., Ltd. | $6,250,000 |
| Daiichi Sankyo Company LTD | $5,998,928 |
| GSK | $5,691,384 |
| Jazz Pharmaceuticals Inc. | $5,055,875 |
| Janssen Research & Development, LLC | $4,712,964 |
| Bayer | $4,228,339 |
| Exelixis Inc. | $4,203,713 |
| Genmab U.S., Inc. | $3,549,752 |
| Tesaro, Inc. | $3,461,400 |
| Agios Pharmaceuticals, Inc. | $3,360,902 |
| Modernatx, Inc. | $2,613,780 |
| Swedish Orphan Biovitrum AB | $2,436,320 |
| Sanofi US Services Inc. | $2,258,637 |
| Beone Medicines USA, Inc. | $1,997,830 |
| Agilent Technologies, Inc. | $1,754,358 |
| Beigene, Ltd. | $1,713,283 |
| Boehringer Ingelheim | $1,707,319 |
| Regeneron | $1,652,061 |
| Incyte Corporation | $1,643,680 |